Endogenous Incretin Secretagogue Compositions as a Mechanistic Class Versus Pharmacological Incretin Receptor Agonists for Weight Reduction in Overweight Adults: A Real-World Observational Cohort Analysis of a Nutraceutical Composition (Trimsulin) and Comparison with Published Outcomes for Semaglutide and Tirzepatide
This observational cohort analysis describes weight-loss outcomes and adverse event rates in 503 overweight adults who completed six months of the "Trimsulin Weight Loss Program," a nutraceutical regimen combining two proprietary products (a powdered drink mix and a capsule) with a structured diet and exercise protocol. The authors compare their results descriptively — without inferential statistics — to published real-world data for the prescription GLP-1 receptor agonist semaglutide and the dual GIP/GLP-1 agonist tirzepatide. The study reports that Trimsulin participants experienced mean weight reductions of 7.3% at 3 months and 14.1% at 6 months, numerically exceeding the comparator figures drawn from a separate published cohort. Adverse events were self-reported by 4.8% of Trimsulin participants versus much higher rates cited for the pharmacological comparators. Key limitations are substantial: there is no randomization, no placebo or active control arm, no blinding, no direct head-to-head comparison, reliance on self-reported adverse events, a highly selected completer-only analysis (503 of 1,000+ enrollees), differing baseline BMI profiles across cohorts, and the absence of any inferential statistical testing. The program's dietary and behavioral components cannot be disentangled from any supplement effect. The authors acknowledge the need for randomized controlled trials. The paper is identified as a preprint.
Why this grade: Single-arm, non-randomized, completer-only cohort (n=503) with no concurrent control group, no blinding, self-reported outcomes, and cross-study comparisons to non-contemporaneous cohorts with different baselines; preprint status means it has not yet undergone peer review.
Abstract Background: Pharmacological glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists such as tirzepatide produce clinically meaningful weight reduction in adults with overweight or obesity. However, gastrointestinal and serious adverse events affect a substantial proportion of treated patients, contributing to discontinuation and limiting long-term adherence. Nutraceutical compositions designed to stimulate endogenous GLP-1 and GIP secretion may offer a tolerability advantage. Objective: To describe weight change and adverse event rates in a real-world cohort of overweight adults using a nutraceutical endogenous incretin secretagogue composition (Trimsulin Weight Loss Program) and to compare these outcomes with publicly available outcome data for semaglutide and tirzepatide. Methods: Observational cohort analysis of 503 overweight adults enrolled in the Trimsulin Weight Loss Program, comprising two nutraceutical products (Control, a powdered drink mix; Thermo, a capsule formulation) taken twice daily before meals, plus a structured dietary protocol and a moderate-exercise recommendation. Body weight, BMI, and participant-reported adverse events were tracked at 12 weeks and 24 weeks. Comparative weight-loss outcomes for semaglutide and tirzepatide were drawn from the on-treatment estimand of the published Truveta-derived real-world cohort analysis by Rodriguez et al. (n = 18,386; mean baseline BMI 39.0). Comparative adverse event rates were drawn from a separate body of clinical trial and pharmacovigilance evidence. Outcomes are reported descriptively; no inferential statistical testing was performed between cohorts. Results: Of more than 1,000 enrolled program participants, 503 completed six months of program participation with protocol-conformant follow-up measurements and constitute the analysis cohort. Mean baseline weight was 201.2 lb (range 130–360); mean BMI was 27.5 (range 20.0–50.1). At 3 months, mean weight reduction was 7.3% in the Trimsulin cohort, compared with 3.6% (semaglutide) and 5.9% (tirzepatide) reported in published comparator data. At 6 months, mean reductions were 14.1%, 5.8%, and 10.1%, respectively. Any adverse event was reported by 4.8% of Trimsulin participants, compared with 89.7% (semaglutide) and 81.0% (tirzepatide) in published trial cohorts. No serious adverse events were reported in the Trimsulin cohort, compared with approximately 3.0% for semaglutide and 5–7% for tirzepatide. These hypothesis-generating findings support further controlled investigation of endogenous incretin secretagogue compositions as a class. The present cohort study evaluated one licensed implementation of the BSM platform framework. Future research directions of highest priority include prospective randomized controlled trials of BSM-framework compositions — including next-generation formulations incorporating more advanced ingredient systems and delivery architectures — compared against placebo and against active pharmacological incretin comparators. Secondary endpoints of particular mechanistic value include changes in plasma active GLP-1 and GIP concentrations, DPP-4 activity, fasting and post-prandial glycemic response, UCP-1 induction, and patient-reported tolerability. A factorial design apportioning the contribution of the BSM supplement components versus the dietary and behavioral program elements would clarify the mechanistic contribution of each. Adjunctive use of BSM-framework compositions in patients who discontinue pharmacological incretin therapy due to intolerance represents a clinically meaningful research direction, given the established real-world discontinuation burden of pharmacological GLP-1 receptor agonists. [11–14] Beyond supplement formats, investigation of BSM-framework ingredient systems in functional food and food-additive delivery formats represents a translational research direction of broader public health relevance, given the potential for population-scale access that food-category routes offer relative to pharmaceutical channels.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.